^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Marginal Zone Lymphoma
    Drug:Jaypirca (pirtobrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Title:

    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) - B-Cell Lymphomas

    Published date:
    04/30/2024
    Excerpt:
    Preferred regimen...Pirtobrutinib (after prior covalent BTKi)